文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

每周卡巴他赛联合同步调强放疗及雄激素剥夺治疗高危前列腺癌的I期试验

Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-02-03

PURPOSE: Cabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer.…

要点

  • 同步卡巴他赛联合放疗及ADT的最大耐受剂量为6 mg/m2。
  • 5年生化无病生存率73%,75%患者为NCCN极高危。
  • 泌尿及肠道患者报告结局无显著最小重要差异,性功能域显著下降。

核心结论

  • 同步卡巴他赛联合放疗及雄激素剥夺治疗的最大耐受剂量为6 mg/m2,高危前列腺癌患者获得稳健的生化控制。

研究设计与样本

  • 患者前瞻性随访安全性、疗效及健康相关生活质量(扩展前列腺指数复合量表)。
  • 疗效采用Phoenix定义进行生化评估。

主要发现

  • 中位随访56个月,同步卡巴他赛的最大耐受剂量为6 mg/m2。
  • 5年生化无病生存率为73%,尽管75%患者按NCCN指南为极高危前列腺癌。
  • 4例患者因剂量限制性毒性(如直肠出血、腹泻和转氨酶升高)未能完成化疗。
  • 扩展前列腺指数复合量表患者报告结局在泌尿域或肠道域无显著最小重要差异,但性功能域显著下降。

关键数值与推荐

  • 同步卡巴他赛联合放疗及雄激素剥夺治疗的最大耐受剂量为6 mg/m2。
  • 5年生化无病生存率为73%。
  • 75%患者为NCCN指南定义的极高危前列腺癌。
  • 4例患者因剂量限制性毒性未完成化疗。

临床怎么用

  • 对于高危前列腺癌,可考虑每周卡巴他赛6 mg/m2联合同步调强放疗及雄激素剥夺治疗。
  • 治疗期间需监测剂量限制性毒性,如直肠出血、腹泻和转氨酶升高。
  • 需关注性功能域患者报告结局的显著下降。

局限性

  • 随访时间中位56个月,长期疗效和毒性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer. The purpose of this study was to determine the maximum tolerated dose for concurrent cabazitaxel with androgen deprivation and intensity modulated radiation therapy in men with high-risk prostate cancer. METHODS AND MATERIALS: Twenty men were enrolled in this institutuional review board-approved phase I clinical trial using a 3 + 3 design. Patients were followed prospectively for safety, efficacy, and health-related quality of life (Expanded Prostate Index Composite). Efficacy was assessed biochemically using the Phoenix definition. RESULTS: With a median follow-up time of 56 months, the maximum tolerated dose of concurrent cabazitaxel was 6 mg/m2. The 5-year biochemical disease-free survival was 73%, despite 75% of patients having very high risk prostate cancer per the National Comprehensive Cancer Network guidelines. Four patients were unable to complete chemotherapy owing to dose-limiting toxicities (eg, rectal bleeding, diarrhea, and elevated transaminase). There was no significant minimally important difference in Expanded Prostate Index Composite patient-reported outcomes for either the urinary or bowel domains; however, there was a significant decrease in the sexual domain. CONCLUSIONS: This is the first clinical trial of prostate cancer to report on the combination of cabazitaxel and radiation therapy. The maximum tolerated dose of concurrent cabazitaxel with radiation and androgen deprivation therapy was determined to be 6 mg/m2. Despite the aggressive nature of the disease, robust biochemical control was observed.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lin J, Den RB, Greenspan J, et al. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32029346. doi:10.1016/j.ijrobp.2019.11.418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。